I just wanted to highlight the following observation;
'Off Label Drug Use may highlight conditions which warrant supplementary clinical trials'.
Off Label use could be cost effective in opening the doorway to study the effect of Trofinetide on a range of neurodevelopmental and neurodegenerative disorders.
- Forums
- ASX - By Stock
- NEU
- Reasons for consideration
Reasons for consideration, page-99
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.45 |
Change
0.000(0.00%) |
Mkt cap ! $1.854B |
Open | High | Low | Value | Volume |
$14.50 | $14.59 | $14.39 | $714.9K | 49.36K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19 | $14.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.46 | 482 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 401 | 14.450 |
6 | 592 | 14.440 |
5 | 378 | 14.430 |
5 | 1514 | 14.420 |
4 | 555 | 14.410 |
Price($) | Vol. | No. |
---|---|---|
14.470 | 438 | 6 |
14.480 | 597 | 5 |
14.490 | 467 | 3 |
14.500 | 3458 | 6 |
14.510 | 1076 | 5 |
Last trade - 11.53am 31/01/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
AII
ALMONTY INDUSTRIES INC.
Lewis Black, President & CEO
Lewis Black
President & CEO
SPONSORED BY The Market Online